DelveInsight’s “Head and Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Head and Neck Squamous Cell Carcinoma, historical and forecasted epidemiology as well as the Head and Neck Squamous Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some Facts of Head and Neck Squamous Cell Carcinoma Market Report:

• According to World Health Organization, 2014, the annual incidence of head and neck cancers worldwide is more than 550,000 cases with around 300,000 deaths each year.
• Male to female ratio ranges from 2:1 to 4:1.
• About 90% of all head and neck cancers are squamous cell carcinomas (HNSCC).
• SCC is the most frequent malignant tumor of the head and neck region.
• HNSCC represents the sixth leading cancer by incidence and there are 500,000 new cases a year worldwide (Kamangar et al., 2006).
• Expected launch of the pipeline therapies shall fuel the growth of the market during the forecast period, i.e., 2021–2030.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market

 

Some of Head and Neck Squamous Cell Carcinoma Companies are:

• Merck
• Sinocelltech Ltd.
• GlaxoSmithKline
• Hoffmann-La Roche
• Kura Oncology
• AVEO Pharmaceuticals, Inc.
• Adlai Nortye
• And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market

 

Head and neck cancer is a term used to define cancer that develops in the mouth (oral cavity), throat, nose, salivary glands, oral cancers or other areas of the head and neck. Most of these are classified as squamous cases which cover the 90% of the disease area.

The TNM staging system of the AJCC maintains uniformity in the staging of head and neck tumors which varies with the anatomic location of the primary tumor. Most patients with head and neck cancer have stage III or IV disease at diagnosis and a few patients present with the early stage disease.

The causes of head and neck cancers are not fully understood. There are certain risk factors that increase the risk of developing the disease such as smoking tobacco, consumption of alcohol and exposure to the human papillomavirus (HPV) which contributes to the development of at least 90% of squamous cell carcinoma of the head and neck. At least 12% of pharyngeal cancer, 3% of oral cancer, and 30–60% of oropharyngeal carcinoma cases are caused by HPV infection.

 

Some of Head and Neck Squamous Cell Carcinoma Therapies are:

• Lenvatinib (E7080/MK-7902)
• SCT-I10A+ chemo
• GSK3359609
• Atezolizumab
• Tipifarnib
• Ficlatuzumab
• Buparlisib (AN2025)
• And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market

 

Scope of Head and Neck Squamous Cell Carcinoma Report:

• The report covers the descriptive overview of Head and Neck Squamous Cell Carcinoma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Head and Neck Squamous Cell Carcinoma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Head and Neck Squamous Cell Carcinoma are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Head and Neck Squamous Cell Carcinoma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Head and Neck Squamous Cell Carcinoma market.

Request for Free Sample Report: https://www.delveinsight.com/sample-request/head-and-neck-squamous-cell-carcinoma-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Head and Neck Squamous Cell Carcinoma

3. Competitive Intelligence Analysis for Head and Neck Squamous Cell Carcinoma

4. Head and Neck Squamous Cell Carcinoma: Market Overview at a Glance

5. Head and Neck Squamous Cell Carcinoma: Disease Background and Overview

6. Patient Journey

7. Head and Neck Squamous Cell Carcinoma Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Head and Neck Squamous Cell Carcinoma Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Head and Neck Squamous Cell Carcinoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Head and Neck Squamous Cell Carcinoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/head-and-neck-squamous-cell-carcinoma-market